Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss

Wegovy® HD demonstrated a mean weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight loss in the STEP UP trialFirst US FDA approval of a GLP-1 treatment under the Commissioner’s National Priority Voucher pilot programme, for products addressing critical US national health prioritiesWegovy® HD complements Wegovy® 2.4 mg, which is already approved in the US for weight management and cardiovascular risk reductionNovo Nordisk expects to launch Wegovy® HD in the US in April 2026 ...